Mohammed Alsalmi
Papers
1
Total Citations
4
H-Index
1
About
Mohammed Alsalmi is a clinical neuroscientist whose research focuses on the pathophysiology and treatment of movement disorders, particularly Parkinson’s disease. His major contribution lies in critically evaluating emerging therapies for levodopa-induced dyskinesia (LID), a debilitating complication of long-term Parkinson’s treatment. In his highly cited review of clinical trial databases, Alsalmi systematically analyzed recent and ongoing trials, revealing that promising pharmacological candidates—such as the 5-HT1A/1B agonist zolmitriptan—failed to meet their endpoints in Phase II studies. He also highlighted the potential of non-pharmacological interventions, notably robot-assisted repetitive transcranial magnetic stimulation (rTMS) of the pre-supplementary motor area, as a novel approach to alleviate dyskinesia. This work has garnered significant attention (4 citations in a short period), underscoring its relevance to clinicians and researchers seeking effective LID treatments. Alsalmi’s synthesis of trial data provides a crucial roadmap for future therapeutic development, making him a key voice in the effort to improve quality of life for Parkinson’s patients.
Research Focus
Key Achievements
Top Papers
- 1